Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Open CTXR dashboard ↗Dare Bioscience, Inc. Common Stock
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Open DARE dashboard ↗